세계의 원내감염증검사 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2025-2033년)

Global Hospital Acquired Disease Testing Market size is anticipated to grow from USD 15.48 Billion in 2024 to USD 66.3 Billion by 2033, showcasing a robust Compound Annual Growth Rate (CAGR) of 17.54% during the forecast period of 2026 to 2033.

The hospital-acquired disease testing market is set to experience robust growth, driven by the increasing incidence of healthcare-associated infections (HAIs) and the growing emphasis on patient safety and quality of care. As hospitals and healthcare facilities strive to minimize the risk of HAIs, the demand for accurate and rapid diagnostic testing methods is becoming paramount. The rise in antibiotic-resistant pathogens further complicates the landscape, necessitating advanced testing solutions that can quickly identify the causative agents of infections and guide appropriate treatment strategies. This growing awareness of the impact of HAIs on patient outcomes and healthcare costs is propelling the market forward.

Technological advancements in diagnostic testing are revolutionizing the hospital-acquired disease testing market. Innovations such as molecular diagnostics, point-of-care testing, and next-generation sequencing are enhancing the speed and accuracy of pathogen detection. These technologies enable healthcare providers to implement timely interventions, reducing the duration of hospital stays and improving overall patient outcomes. Additionally, the integration of digital health solutions, including electronic health records and laboratory information systems, is streamlining data management and facilitating better communication among healthcare teams, further enhancing the efficiency of infection control measures.

Moreover, the hospital-acquired disease testing market will benefit from increased regulatory scrutiny and public health initiatives aimed at reducing HAIs. As healthcare organizations adopt stringent infection prevention protocols, the demand for comprehensive testing solutions will rise. Collaborative efforts between diagnostic companies, healthcare providers, and regulatory bodies will be essential in developing standardized testing guidelines and ensuring the widespread adoption of best practices. As the market evolves, the focus will shift towards integrating testing into broader infection control strategies, emphasizing the importance of surveillance, early detection, and targeted interventions in combating hospital-acquired diseases.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

SEGMENTATION COVERED IN THE REPORT

By Test Type

• Urinary Tract Infection
• Surgical Site Infection
• Pneumonia Stents
• Blood Stream Infection
• Methicillin-Resistant Staphylococcus Aureus
• Others

By End User

• Hospitals and Intensive Care Units (ICUS)
• Ambulatory Surgical and Diagnostic Centers
• Nursing Homes and Maternity Centers
• Companies
• COMPANIES PROFILED
• Abbott
• Eurofins Scientific
• BIOMERIEUX
• Cantel Medical
• Meridian Bioscience Inc.
• QIAGEN
• F. Hoffmann-La Roche Ltd
• BD
• Hologic Inc.
• Siemens Healthcare Private Limited
• Thermo Fisher Scientific Inc.
• Medtronic
• Getinge AB
• The above list can be customized.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. HOSPITAL ACQUIRED DISEASE TESTING INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porters Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Test Type
  • 3.7.2 Market Attractiveness Analysis By End User
  • 3.7.3 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL HOSPITAL ACQUIRED DISEASE TESTING MARKET ANALYSIS BY TEST TYPE

• 5.1. Overview By Test Type
• 5.2. Historical and Forecast Data Analysis By Test Type
• 5.3. Urinary Tract Infection Historic and Forecast Sales By Regions
• 5.4. Surgical Site Infection Historic and Forecast Sales By Regions
• 5.5. Pneumonia Stents Historic and Forecast Sales By Regions
• 5.6. Blood Stream Infection Historic and Forecast Sales By Regions
• 5.7. Methicillin-Resistant Staphylococcus Aureus Historic and Forecast Sales By Regions
• 5.8. Others Historic and Forecast Sales By Regions

6. GLOBAL HOSPITAL ACQUIRED DISEASE TESTING MARKET ANALYSIS BY END USER

• 6.1. Overview By End User
• 6.2. Historical and Forecast Data Analysis By End User
• 6.3. Hospitals and Intensive Care Units (ICUS) Historic and Forecast Sales By Regions
• 6.4. Ambulatory Surgical and Diagnostic Centers Historic and Forecast Sales By Regions
• 6.5. Nursing Homes and Maternity Centers Historic and Forecast Sales By Regions
• 6.6. Companies Historic and Forecast Sales By Regions

7. GLOBAL HOSPITAL ACQUIRED DISEASE TESTING MARKET ANALYSIS BY GEOGRAPHY

• 7.1. Regional Outlook
• 7.2. Introduction
• 7.3. North America Sales Analysis
  • 7.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 7.3.2 North America By Segment Sales Analysis
  • 7.3.3 North America By Country Sales Analysis
  • 7.3.4 United States Sales Analysis
  • 7.3.5 Canada Sales Analysis
  • 7.3.6 Mexico Sales Analysis
• 7.4. Europe Sales Analysis
  • 7.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 7.4.2 Europe By Segment Sales Analysis
  • 7.4.3 Europe By Country Sales Analysis
  • 7.4.4 United Kingdom Sales Analysis
  • 7.4.5 France Sales Analysis
  • 7.4.6 Germany Sales Analysis
  • 7.4.7 Italy Sales Analysis
  • 7.4.8 Russia Sales Analysis
  • 7.4.9 Rest Of Europe Sales Analysis
• 7.5. Asia Pacific Sales Analysis
  • 7.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 7.5.2 Asia Pacific By Segment Sales Analysis
  • 7.5.3 Asia Pacific By Country Sales Analysis
  • 7.5.4 China Sales Analysis
  • 7.5.5 India Sales Analysis
  • 7.5.6 Japan Sales Analysis
  • 7.5.7 South Korea Sales Analysis
  • 7.5.8 Australia Sales Analysis
  • 7.5.9 South East Asia Sales Analysis
  • 7.5.10 Rest Of Asia Pacific Sales Analysis
• 7.6. Latin America Sales Analysis
  • 7.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 7.6.2 Latin America By Segment Sales Analysis
  • 7.6.3 Latin America By Country Sales Analysis
  • 7.6.4 Brazil Sales Analysis
  • 7.6.5 Argentina Sales Analysis
  • 7.6.6 Peru Sales Analysis
  • 7.6.7 Chile Sales Analysis
  • 7.6.8 Rest of Latin America Sales Analysis
• 7.7. Middle East & Africa Sales Analysis
  • 7.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 7.7.2 Middle East & Africa By Segment Sales Analysis
  • 7.7.3 Middle East & Africa By Country Sales Analysis
  • 7.7.4 Saudi Arabia Sales Analysis
  • 7.7.5 UAE Sales Analysis
  • 7.7.6 Israel Sales Analysis
  • 7.7.7 South Africa Sales Analysis
  • 7.7.8 Rest Of Middle East And Africa Sales Analysis

8. COMPETITIVE LANDSCAPE OF THE HOSPITAL ACQUIRED DISEASE TESTING COMPANIES

• 8.1. Hospital Acquired Disease Testing Market Competition
• 8.2. Partnership/Collaboration/Agreement
• 8.3. Merger And Acquisitions
• 8.4. New Product Launch
• 8.5. Other Developments

9. COMPANY PROFILES OF HOSPITAL ACQUIRED DISEASE TESTING INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Market Concentration Rate
• 9.3. Abbott
  • 9.3.1 Company Overview
  • 9.3.2 Company Revenue
  • 9.3.3 Products
  • 9.3.4 Recent Developments
• 9.4. Eurofins Scientific
  • 9.4.1 Company Overview
  • 9.4.2 Company Revenue
  • 9.4.3 Products
  • 9.4.4 Recent Developments
• 9.5. BIOMÉRIEUX
  • 9.5.1 Company Overview
  • 9.5.2 Company Revenue
  • 9.5.3 Products
  • 9.5.4 Recent Developments
• 9.6. Cantel Medical
  • 9.6.1 Company Overview
  • 9.6.2 Company Revenue
  • 9.6.3 Products
  • 9.6.4 Recent Developments
• 9.7. Meridian Bioscience Inc.
  • 9.7.1 Company Overview
  • 9.7.2 Company Revenue
  • 9.7.3 Products
  • 9.7.4 Recent Developments
• 9.8. QIAGEN
  • 9.8.1 Company Overview
  • 9.8.2 Company Revenue
  • 9.8.3 Products
  • 9.8.4 Recent Developments
• 9.9. F. Hoffmann-La Roche Ltd
  • 9.9.1 Company Overview
  • 9.9.2 Company Revenue
  • 9.9.3 Products
  • 9.9.4 Recent Developments
• 9.10. BD
  • 9.10.1 Company Overview
  • 9.10.2 Company Revenue
  • 9.10.3 Products
  • 9.10.4 Recent Developments
• 9.11. Hologic Inc.
  • 9.11.1 Company Overview
  • 9.11.2 Company Revenue
  • 9.11.3 Products
  • 9.11.4 Recent Developments
• 9.12. Siemens Healthcare Private Limited
  • 9.12.1 Company Overview
  • 9.12.2 Company Revenue
  • 9.12.3 Products
  • 9.12.4 Recent Developments
• 9.13. Thermo Fisher Scientific Inc.
  • 9.13.1 Company Overview
  • 9.13.2 Company Revenue
  • 9.13.3 Products
  • 9.13.4 Recent Developments
• 9.14. Medtronic
  • 9.14.1 Company Overview
  • 9.14.2 Company Revenue
  • 9.14.3 Products
  • 9.14.4 Recent Developments
• 9.15. Getinge AB
  • 9.15.1 Company Overview
  • 9.15.2 Company Revenue
  • 9.15.3 Products
  • 9.15.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies